Abstract
The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 36-39 |
| Number of pages | 4 |
| Journal | Trends in Cardiovascular Medicine |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 1991 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
}
New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates. / Vaughan, Douglas E.; Loscalzo, Joseph.
In: Trends in Cardiovascular Medicine, Vol. 1, No. 1, 01.01.1991, p. 36-39.Research output: Contribution to journal › Short survey
TY - JOUR
T1 - New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates
AU - Vaughan, Douglas E.
AU - Loscalzo, Joseph
PY - 1991/1/1
Y1 - 1991/1/1
N2 - The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.
AB - The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.
UR - http://www.scopus.com/inward/record.url?scp=0025767042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025767042&partnerID=8YFLogxK
U2 - 10.1016/1050-1738(91)90057-L
DO - 10.1016/1050-1738(91)90057-L
M3 - Short survey
VL - 1
SP - 36
EP - 39
JO - Trends in Cardiovascular Medicine
JF - Trends in Cardiovascular Medicine
SN - 1050-1738
IS - 1
ER -